TAPI, or Technology & API Services, appointed Serge Rogasik as its Chief Executive Officer on Sept. 30, 2026. He will lead the global business spanning active pharmaceutical ingredients, customized CDMO services, scientific and technical capabilities, and operations across India, the Middle East, Europe and the Americas. TAPI says it has more than 4,000 employees, 13 manufacturing sites, six R&D facilities and a portfolio of more than 350 active ingredients, while its company overview lists 4,100 employees and operations in more than 100 countries. Rogasik brings more than 25 years of experience across specialty ingredients, active ingredients, specialty chemicals and life sciences, most recently serving as President and Chief Executive Officer of Kensing. He and TAPI executives are scheduled to attend CPHI Milan from Oct. 6 to Oct. 8, 2026.